Pressmeddelanden, rapporter och bolagsmeddelande för Curasight
Spotlight News
Nyhetsuppdatering från Curasight
Press release from Companies: Curasight announces brain cancer as first indication for uTREAT[®]: First patient to be dosed Q2 2025
Spotlight News
Nyhetsuppdatering från Curasight
Press release from Companies: Curasight announces brain cancer as first indication for uTREAT[®]: First patient to be dosed Q2 2025
Spotlight News
Nyhetsuppdatering från Curasight
Press release from Companies: Curasight to present at Dansk Aktionærforening InvestorDagen
Spotlight News
Nyhetsuppdatering från Curasight
Press release from Companies: Clinical phase II trial of uPAR-PET in brain cancer patients published; data supports development of uTREAT for brain cancer
Spotlight News
Nyhetsuppdatering från Curasight
Press release from Companies: Curasight A/S announces last day of trading in BTU and first day of trading in warrant series TO2 and TO3
Spotlight News
Nyhetsuppdatering från Curasight
Press release from Companies: Curasight A/S announces last day of trading in BTU and first day of trading in warrant series TO2 and TO3
Spotlight News
Nyhetsuppdatering från Curasight
Press release from Companies: Curasight A/S rights issue heavily oversubscribed
Spotlight News
Nyhetsuppdatering från Curasight
Press release from Companies: Commencement of subscription period in Curasight’s preferential rights issue
Spotlight News
Nyhetsuppdatering från Curasight
Press release from Companies: Curasight A/S publishes prospectus due to upcoming rights issue
Spotlight News
Nyhetsuppdatering från Curasight
Press release from Companies: Curasight A/S publishes prospectus due to upcoming rights issue